SCHEMBL23833570

SCHEMBL23833570

N#Cc1ccc(C(C(=O)O)C(=O)C2CC2)cc1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.39
KDM4E B2RXH2 2/20 0.38
GAA P10253 1/20 0.38
MAPT P10636 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
GSK3B P49841 1/20 0.38
SRC P12931 1/20 0.37
NSD2 O96028 1/20 0.37
CA1 P00915 2/20 0.37
CA2 P00918 2/20 0.37
PAX8 Q06710 2/20 0.36
EPHX1 P07099 2/20 0.36
NOTUM Q6P988 1/20 0.36
UBE2N P61088 1/20 0.36
HSD11B1 P28845 1/20 0.36
EPHX2 P34913 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23833545 0.82 TSHR (0.43) TSHRKDM4ENPC1RAB9APAX8
SCHEMBL8007655 0.79 SRC (0.61) GAAMAPTSRC
SCHEMBL9666479 0.79 ITK (0.43) TSHRKDM4EGAAMAPTL3MBTL1
SCHEMBL11219485 0.71 GSK3B (0.47) TSHRKDM4EGAAMAPTL3MBTL1
SCHEMBL4108609 0.71 UBE2N (0.44) KDM4EGAAMAPTNPC1RAB9A
SCHEMBL1565554 0.71 NPC1 (0.48) TSHRMAPTNPC1RAB9ANSD2
SCHEMBL2763299 0.70 SRC (0.48) NPC1RAB9ASRCHSD11B1
SCHEMBL8953567 0.70 GSK3B (0.51) KDM4ENPC1RAB9AGSK3BNSD2
SCHEMBL7446955 0.70 CA1 (0.55) NPC1RAB9AGSK3BCA1CA2
SCHEMBL8975203 0.70 LMNA (0.56) TSHRKDM4EGAAMAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2023-05-25 US disclosed
EP-4121426-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE Akebia Therapeutics Inc. (US) 2023-01-25 EP disclosed
CN-115515948-A PHD inhibitor compounds, compositions and uses 阿克比治疗有限公司 2022-12-23 CN disclosed
WO-2021188938-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE AKEBIA THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159489-A1 PHD INHIBITOR COMPOUNDS, COMPOSITIONS, AND USE HIF1AN, EGLN3, PHF20 TSHR 4420/4885KDM4E 69/4885GAA 3851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.